- AstraZeneca's (AZN, Financial) Q1 results show robust growth in key sectors, boosting confidence in its future earnings.
- Analyst projections indicate a significant upside potential, with a mean price target suggesting a 42.60% increase.
- Current investment sentiment classifies AstraZeneca as "Outperform," bolstered by promising GF Value projections.
AstraZeneca (AZN) reported an impressive first quarter, showcasing its financial prowess with a Non-GAAP EPS of $2.49. The company achieved a 10% surge in total revenue, reaching $13.59 billion, driven primarily by exceptional performances in its Oncology and BioPharmaceuticals divisions. This positive trend has reaffirmed AstraZeneca's fiscal year 2025 forecasts, expecting high single-digit revenue growth alongside low double-digit EPS growth.
Wall Street Analysts' Insights
The latest analysis from 11 Wall Street financial experts presents an intriguing picture for investors. AstraZeneca PLC (AZN, Financial) carries an average one-year price target of $99.72. Projections highlight a high target of $231.66 and a low of $67.00. The consensus suggests a potential upside of 42.60% from the current trading price of $69.93. For a detailed analysis, visit the AstraZeneca PLC (AZN) Forecast page.
Further analysis from 13 brokerage firms places AstraZeneca PLC (AZN, Financial) firmly in the "Outperform" category with an average brokerage recommendation of 1.8. This rating system ranges from 1 to 5, where 1 indicates a Strong Buy and 5 signals a Sell.
Understanding GF Value Estimations
GuruFocus's GF Value estimate paints an optimistic picture for AstraZeneca's future. In one year, the projected GF Value for AstraZeneca PLC (AZN, Financial) is $87.35, projecting a 24.91% increase from its present market price of $69.93. The GF Value offers a fair value estimate, derived from historical trading multiples and potential business growth assessments. For more comprehensive insights, please see the AstraZeneca PLC (AZN) Summary page.
